Ling Zhang

Renmin University of China, Peping, Beijing, China

Are you Ling Zhang?

Claim your profile

Publications (6)2.51 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: In recent years, there has been a large number of studies and reports about the efficacy and safety of recombinant human endostatin (rh-endostatin), an anti-angiogenic drug, in treatment of advanced lung cancer. Authentic assessment of rh-endostatin treatment in lung cancer is important. The aim of this study is to assess the clinical efficacy and safety of rh-endostatin combined with chemotherapy in the treatment of patients with non-small cell lung cancer (NSCLC). Cochrane systematic review methods were used in the data selection, and data were selected from the Cochrane Library, EMBASE, Medline, SCI, CBM, CNKI, and etc electronic database to get all clinical controlled trials. The retrieval time was March 2010. The objects of these randomized controlled trials were advanced NSCLC patients and in the experimental group was rh-endostatin combination chemotherapy, in the control group was chemotherapy alone to compare the efficacy of two groups. The quality of included trials were evaluated by two reviewers independently. The software RevMan 5.0 was used for meta-analyses. Fifteen trials with 1,326 patients were included according to the including criterion. All trials were randomized controlled trials, and two trials were adequate in reporting randomization. Thirteen trials didn't mention the blinding methods. Meta analysis indicated that the NPE arm (Vinorelbine+cisplatin+rh-endostatin) had a different response rate compared with NP (Vinorelbine+cisplatin) arm (OR=2.16, 95%CI: 1.57-2.99). The incidences of severe leukopenia (OR=0.94, 95%CI: 0.66-1.32) and severe thrombocytopenia (OR=1.00, 95%CI: 0.64-1.57) and nausea and vomiting (OR=0.85, 95%CI: 0.61-1.20) were similar in the NPE arm compared with those in the NP arm. The NPE plus radiotherapy (RT) arm had a similar response rate compared with NP plus RT arm (OR=2.39, 95%CI: 0.99-5.79). The incidences of leukopenia (OR=0.83, 95%CI: 0.35-1.94) and thrombocytopenia (OR=0.78, 95%CI: 0.19-3.16) and radiation esophagitis (OR=1.00, 95%CI: 0.40-2.49) were similar in the NPE plus RT arm compared with those in the NP plus RT arm. In the treatment of advanced NSCLC, rh-endostatin in combination with platinum-based chemotherapy improve the response rate without obviously raised side effects, however, when radiotherapy are added to NPE arm or NP arm, the response rates have a similar outcome. Owing to the small sample size and poor quality of included trials, more well-designed double-blinded randomized controlled trials should be performed.
    Zhongguo fei ai za zhi = Chinese journal of lung cancer 05/2011; 14(5):404-13.
  • [Show abstract] [Hide abstract]
    ABSTRACT: To study the effect of endostar on the expression of hypoxia-inducible factor 1 (HIF-1) and vascular endothelial growth factor (VEGF) and radiosensitization, the changes of A549 cells treated by endostar, radiotherapy and radiotherapy plus endostar were checked by flow cytometry (FCM), methyl thiazolyl tetrazolium (MTT), hoechst staining, and enzyme linked immunosorbent assay (ELISA). The results showed that endostar could block cell periods of A549 and stopped the cell cycle at G2/M and S periods. Cell growth inhibiting and apoptotic rate in the combination group were higher than those in other groups. Meanwhile, the levels of HIF-1 and VEGF expression in the combination group were lower than those of other groups. It suggested that endostar significantly sensitizes the function of radiation in A549 cells by arresting the cell cycle at stage of G2/M and S, increasing the cell growth inhibiting and the apoptotic rate, down-regulating the expression of HIF-1 and VEGF.
    Molecular Biology Reports 05/2011; 39(1):89-95. · 2.51 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In order to investigate the efficacy of combining radiation therapy with endostar on Lewis lung carcinoma in mice and the interaction mechanisms of combined therapy. Tumor models were established in the hind limb of female C57 BL/6N mice by subcutaneous transplantation. The tumor-bearing mice were randomly divided into 4 groups: control group, endostar group (20 mg·kg−1, once daily for 15 days), radiotherapy group (2 Gray per day to 10 Gray, d6-d10), and radiotherapy plus endostar group (combination group), (n=10 in each group). The tumors were applied to analysis of the tumor inhibitory rate and growth curve. Immunohistochemisty was adopted to check the expressions of microvessel density (MVD). The expression levels of Hypoxia-inducible factor 1α (HIF-1α) mRNA was tested by real-time fluorescence quantitative polymerase chain reaction (RT-PCR). The results demonstrated that the tumor inhibitory rate in combined treatment group was higher than that in other groups. Meanwhile, MVD and the level of HIF-1α mRNA were lower than that in other groups. We concluded that endostar significantly sensitized the function of radiation on Lewis lung carcinoma in mice, and this effect is working by decreasing HIF-1α, thereby increasing the killing effect of radiation on tumor cells.
    4th International Conference on Biomedical Engineering and Informatics, BMEI 2011, Shanghai, China, October 15-17, 2011; 01/2011
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hypoxia-inducible factor 1 (HIF-1) and vascular endothelial growth factor (VEGF) play important roles in tumor angiogenesis. We examined the effect of endostar, an inhibitor of angiogenesis on the expression of HIF-1 and VEGF and on angiogenesis and radio sensitization. Flow cytometry (FCM) was used to evaluate the cell cycle phase distribution affected by endostar. The cell growth inhibiting rate was detected by methyl thiazolyl tetrazolium (MTT). Hoechst staining displayed the apoptotic cells, the expression of HIF-1 and VEGF was determined by enzyme linked immunosorbent assay (Elisa). To explore the anti-tumor efficacy in vivo, Lewis lung cancer models were established in the hind limb of female C57BL/6J mice by subcutaneous transplantation. We calculated the tumor inhibitory rate and detected the microvessel density (MVD) and VEGF expression by Immunohistochemistry. Whether in vitro or in vivo, endostar in combination with radiotherapy (RT) had the most significant inhibitory effect. Endostar had the function of block cell periods on A549 and stopped the cell cycle at G2/M and S periods. It also decreased the expression of HIF-1 and VEGF induced by radiotherapy. Endostar combined with irradiation had synergistic anti-tumor effect. And the mechanism may be that endostar can arrest the cell cycle at stage of G2/M and S, thereby, inhibiting the proliferation of tumor cells. In addition, the inhibition of HIF-1 and VEGF which play important role in resistant of radiotherapy may contribute to the synergistic effect.
    01/2010;
  • [Show abstract] [Hide abstract]
    ABSTRACT: ObjectiveThe aim of our study was to evaluate the short-term efficacy and the toxic reaction of nedaplatin concurrent with radiotherapy for mid-advanced nasopharyngeal carcinoma and esophageal carcinoma. MethodsThirty-four patients were confirmed diagnosis with cancer by pathologic results. All patients were given 6MV X-ray for radiotherapy, Dt 66–70 Gy/33–35 f/6–7 w, concurrently administrated nedaplatin (30 mg/m2) once a week (6 times). ResultsA total 34 patients were enrolled, of whom 33 patients were available for objective response, 1 patient of esophageal cancer quit for allergic reaction. The response rate (RR) of nedaplatin-contained therapy for nasopharyngeal carcinoma and esophageal carcinoma were 90.0% and 76.9%, respectively. The major toxic reaction was bone marrow suppression observed in 25 patients (73.5%), in which grade III aleukocytosis was observed in 3 patients (8.8%), grade III + IV thrombocytopenia in 3 patients (8.8%). And 6 patients (17.6%) showed gastrointestinal tract reaction. There were 4 patients with radiation esophagitis in the 13 patients with esophageal carcinoma. ConclusionNedaplatin can increase the therapeutic effect of radiation. Its incidence rate of bone marrow suppression is high, but the gastrointestinal tract reaction and renal toxicity is low and mild. Key wordsnedaplatin-nasopharyngeal carcinoma-esophageal carcinoma-toxic reaction
    The Chinese-German Journal of Clinical Oncology 9(11):652-655.
  • [Show abstract] [Hide abstract]
    ABSTRACT: ObjectiveThe aim of our study was to observe the efficacy and toxicity of 50 cases of advanced non-small cell lung cancer (NSCLC) patients treated by pemetrexed. MethodsFifty patients, including 29 females and 21 males, with a median age 62 years (35–82 years), 13 of whom were treated with pemetrexed only and the left 37 cases were treated with pemetrexed combined with platinum in the Department of Oncology, Renmin Hospital of Wuhan University from June 2006 to March 2009. Single agent regimen: patients received pemetrexed 500 mg/m2 on day 1 with every 21 days. Combination regimen: patients received pemetrexed 500 mg/m2 on day 1 and carboplatin 300 mg/m2 on day 1 or cisplatin 35 mg/m2 on day 1 to day 3 or nedaplatin 80 mg/m2 on day 1 by intravenous infusion with 21 days as one cycle. RECIST 1.0 standard was used to evaluate the clinical efficiency, and the WHO toxicity standard was used to evaluate toxic reaction, and the QOL was used to evaluate the quality of life. ResultsAll patients were given 162 cycles (at least 2 cycles, at most 6 cycles) and the response rate of all the patients were evaluated. There were 2 complete remission (CR), 7 partial remission (PR), 22 stable disease (SD) and 19 progressive disease (PD) in the group, the overall response rate was (RR) was 18.0% and disease control rate (DCR) 62.0%. The quality of life improvement rate reaches 58.0%. The major toxic reaction included neutropenia, thrombocytopenia, hypemia, nausea, and vomiting. Most of the severity of these effects was grade I–II and well tolerated. ConclusionChemotherapy with pemetrexed or pemetrexed combined with platinum in the treatment of advanced non-small cell lung cancer is effective, safe and well-tolerable, which can improve quality of life of the patient. Key wordsnon-small-cell lung cancer–pemetrexed–chemotherapy
    The Chinese-German Journal of Clinical Oncology 10(3):140-143.